Medical teams rarely write everything in-house. Manuscripts, regulatory submissions, and clinical communications routinely pass through medical communications agencies, contract research organizations, and freelance medical writers before they’re finished.<\/p>\n
That matters for GDPR compliance in a way that’s easy to overlook. GDPR doesn’t just apply to the pharma company or hospital that owns the data. It applies to every agency, writer, and tool that touches it along the way.<\/p>\n
GDPR treats health information as special category data under Article 9, a stricter classification than ordinary personal data. Processing it generally requires explicit consent or another specific legal basis, not just a general data processing justification.<\/p>\n
This matters directly for medical writing, because a manuscript, case report, or regulatory document often contains exactly this kind of information, even in draft form. A document doesn’t need to be “finished” or “published” for GDPR’s special category rules to apply. The moment it contains identifiable patient information, those stricter protections are already in effect.<\/p>\n
These two terms get used interchangeably in practice, and the difference actually changes which GDPR rules apply.<\/p>\n
A lot of clinical documentation that teams assume is “anonymized” is actually pseudonymized. That distinction decides whether GDPR still applies to a given document, and it’s worth getting right before assuming a draft is safe to share broadly.<\/p>\n
Medical writing work often crosses borders. An EU-based trial might use a writing agency based outside the EEA, or a cloud-based writing tool might process documents on servers located in another jurisdiction entirely.<\/p>\n
GDPR places specific restrictions on transferring personal data, including health data, outside the EEA. This applies whether the transfer happens through an outsourced writing vendor or through the servers a software tool runs on. A medical writing solution that doesn’t disclose where it processes data creates a transfer risk that’s easy to miss until a data protection officer asks about it directly.<\/p>\n
GDPR gives individuals a right to request erasure of their personal data. Clinical trials and regulatory submissions, on the other hand, often carry legal requirements to retain documentation for years, sometimes well beyond when a trial concludes.<\/p>\n
These two obligations can pull in opposite directions, and resolving the tension usually depends on the specific legal basis for processing and the retention requirements of the relevant regulatory framework. It’s a conversation worth having with legal or compliance counsel early, rather than assuming either requirement automatically overrides the other.<\/p>\n
A Data Protection Impact Assessment isn’t just an internal exercise for the organization that owns the data. If an agency, freelance writer, or software tool is going to touch health-related content, that same scrutiny should extend to them.<\/p>\n
In practice, this means asking the same questions of an external medical writing vendor or an AI writing tool that you’d ask of your own internal process:<\/p>\n
A vendor or tool that can’t answer these clearly is a gap in your own GDPR compliance, not just theirs.<\/p>\n